세계의 피임약 및 피임기구 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별 부문 예측(2025-2030년)

Contraceptive Drugs And Devices Market Size, Share & Trends Analysis Report By Product (Contraceptive Drugs (Pills, Patch, Injectable), Contraceptive Devices), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

시장 규모와 동향

세계의 피임약 및 피임기구 시장 규모는 2024년 311억 8,000만 달러로, 2025-2030년까지 CAGR 6.0%를 나타낼 것으로 예측됩니다.

피임약 시장의 성장에는 몇 가지 요인이 기여합니다. 생식 헬스에 대한 인식과 교육 증가, 가족계획법에 대한 수요 증가, 의료 인프라와 접근의 개선, 보다 효과적이고 편리한 피임 옵션에 대한 소비자의 기호의 변화 등이 주요 촉진요인입니다. 이러한 요인들로 인해 경구 피임약, 자궁내 피임기구(IUD), 임플란트 등의 장시간 작용형 가역적 피임약(LARC) 등 폭넓은 피임법의 선택이 세계적으로 요구되고 있습니다.

게다가 10대 임신에 대한 건강 우려, 최신 피임법에 대한 의식이 높아지고, 계획 밖의 임신을 막는 주요 수단으로서의 경구 피임약에 대한 기호 증가가 예측 기간 동안 시장 성장을 가속할 것으로 예상됩니다. 또한 제품 혁신의 진전, 정부의 이니셔티브, 여성의 힘과 권리의 중요성이 이 시장 성장에 기여하고 있습니다. 예를 들어, 2023년 7월에는 프로게스틴 경구 피임약인 Opill이 FDA로부터 비배합용으로 승인을 받았습니다.

원치 않는 임신과 관련 의료 비용 절감을 목적으로 한 프로그램의 실행과 사용자 간의 의식 향상은 예측 기간 동안 산업 성장을 가속할 것으로 예상됩니다. 유엔인구기금(UNFPA)의 '2022년 세계인구현황보고서'에 따르면, 세계에서는 매년 약 1억 2,100만 명이 임신하고 있으며, 절반 가까이가 원하지 않는 임신입니다.

또한 개발도상국 정부는 피임에 대한 인식과 접근성을 높이기 위한 조치를 취하고 있습니다. 예를 들어, 2023년 10월, 인도의 카르나타카 보건부는 국가 가족 계획 프로그램 하에서 여성을 위한 두 가지 새로운 피임법을 시작했습니다. 피하 임플란트와 피하 주사는 정부가 운영하는 보건 센터에서 사용할 수 있으며, 두 번의 출산 간격을 연장하여 생식과 성 건강을 촉진합니다. 이러한 피임법은 신흥국 시장에서의 피임을 촉진하고 시장 개척에 공헌할 것으로 기대되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 피임약 및 피임기구 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 동향
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 산업의 과제
  • 시장 기회 분석
• 피임약 및 피임기구 시장 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 피임약 및 피임 기구 시장 : 제품별, 추정 및 동향 분석

• 정의와 범위
• 제품 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 피임약 및 피임 기구 시장 :제품별, 2018-2030년
  • 피임약
  • 피임기구

제5장 피임약 및 피임 기구 시장 :지역별, 추정 및 동향 분석

• 정의와 범위
• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 피임약 및 피임기구 시장 점유율, 지역별, 2024년과 2030년,
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 최근의 동향/주요 시장 진출기업에 의한 전략적 이니셔티브와 영향 분석
• 기업 분류
• 기업의 시장 포지셔닝 분석
• 전략 매핑
• 기업 프로파일
  • AbbVie Inc.
  • Afaxys, Inc.
  • Agile Therapeutics
  • Bayer AG
  • China Resources(Holdings) Co., Ltd.
  • Church & Dwight Co., Inc.
  • Cupid Limited
  • Helm AG
  • Johnson & Johnson Services, Inc.
  • Organon Group
  • Pfizer Inc.
  • Veru, Inc.
  • Viatris Inc.

JHS

영문 목차

영문목차

Market Size & Trends:

The global contraceptive drugs and devices market size was estimated at USD 31.18 billion in 2024 and is projected to grow at a CAGR of 6.0% from 2025 to 2030. Several factors are contributing to the growth of the contraceptive market. Increasing awareness and education about reproductive health, a rising demand for family planning methods, improved healthcare infrastructure and access, and a shift in consumer preferences toward more effective and convenient contraceptive options are all key drivers. These factors have led to a global demand for a wide range of contraceptive choices, including oral contraceptives and long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants.

Furthermore, health concerns related to teenage pregnancies, increased awareness of modern contraception methods, and a growing preference for oral contraceptives as the primary means of preventing unplanned pregnancies are anticipated to drive market growth during the forecast period. In addition, advancements in product innovation, government initiatives, and a focus on women's empowerment and rights have contributed to this market growth. For instance, in July 2023, Opill, a progestin-only oral contraceptive pill, got approval by the FDA for nonprescription use.

Implementing programs aimed at reducing unwanted pregnancies and related healthcare costs, along with increasing awareness among users, is expected to drive growth in the industry during the forecast period. According to the 2022 State of World Population Report by the United Nations Population Fund (UNFPA), approximately 121 million pregnancies occur worldwide each year, with nearly half of them being unintended.

Moreover, governments in developing countries are undertaking steps to increase awareness and access to contraceptives. For instance, in October 2023, the Karnataka Health Department in India launched two new contraceptive methods for women under the National Family Planning Programme. The sub-dermal implant and subcutaneous injection were made available at government-run health centers to promote reproductive and sexual health by extending the interval between two births. Such methods are expected to promote the use of contraception in developing countries and contribute to the market's growth.

Global Contraceptive Drugs And Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global contraceptive drugs and devices market report based on product, and region.

• Product Outlook (Revenue, USD Billion, 2018 - 2030)
• Contraceptive Drugs
  • Contraceptive Pills
  • Patch
  • Injectable
• Contraceptive Devices
  • Condoms
  • Male Condoms
  • Female Condoms
  • Subdermal Implants
  • Intrauterine Devices (IUDs)
  • Copper IUDs
  • Hormonal IUDs
  • Vaginal Ring
  • Diaphragm
• Regional Outlook (Revenue, USD Billion, 2018-2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Secondary Sources
  • 1.4.2. List of Primary Sources
  • 1.4.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Contraceptive Drugs and Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamic
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing awareness and education on reproductive health
    • 3.2.1.2. Rising demand for family planning methods
    • 3.2.1.3. Growing healthcare infrastructure and access
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Side effects and health concerns
  • 3.2.3. Industry Challenges
  • 3.2.4. Market Opportunity Analysis
• 3.3. Contraceptive Drugs and Devices Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Contraceptive Drugs and Devices Market: Product Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Contraceptive Drugs and Devices Market: By Product, 2018 to 2030
  • 4.4.1. Contraceptive Drugs
    • 4.4.1.1. Contraceptive Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.2. Contraceptive Pills
      • 4.4.1.2.1. Contraceptive Pills Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.3. Patch
      • 4.4.1.3.1. Patch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.4. Injectable
      • 4.4.1.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4.2. Contraceptive Devices
    • 4.4.2.1. Contraceptive Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2.2. Condoms
      • 4.4.2.2.1. Condoms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.2.2.2. Male Condoms
        • 4.4.2.2.2.1. Male Condoms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.2.2.3. Female Condoms
        • 4.4.2.2.3.1. Female Condoms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2.3. Subdermal Implants
      • 4.4.2.3.1. Subdermal Implants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2.4. Intrauterine Devices (IUDs)
      • 4.4.2.4.1. Intrauterine Devices (IUDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.2.4.2. Copper IUDs
        • 4.4.2.4.2.1. Copper IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.2.4.3. Hormonal IUDs
        • 4.4.2.4.3.1. Hormonal IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2.5. Vaginal Ring
      • 4.4.2.5.1. Vaginal Ring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2.6. Diaphragm
      • 4.4.2.6.1. Diaphragm Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Contraceptive Drugs and Devices Market: Regional Estimates & Trend Analysis by Region, Product

• 5.1. Definition and Scope
• 5.2. Regional Market Share Analysis, 2024 & 2030
• 5.3. Regional Market Dashboard
• 5.4. Contraceptive Drugs and Devices Market Share, By Region, 2024 & 2030, (USD Billion)
• 5.5. North America
  • 5.5.1. North America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.2. U.S.
    • 5.5.2.1. U.S. Key Country Dynamics
    • 5.5.2.2. Regulatory Landscape and Reimbursement Scenario
    • 5.5.2.3. Competitive Insights
    • 5.5.2.4. U.S. Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.3. Canada
    • 5.5.3.1. Canada Key Country Dynamics
    • 5.5.3.2. Regulatory Landscape and Reimbursement Scenario
    • 5.5.3.3. Competitive Insights
    • 5.5.3.4. Canada Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.4. Mexico
    • 5.5.4.1. Mexico Key Country Dynamics
    • 5.5.4.2. Regulatory Landscape and Reimbursement Scenario
    • 5.5.4.3. Competitive Insights
    • 5.5.4.4. Mexico Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Europe
  • 5.6.1. Europe Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.2. UK
    • 5.6.2.1. UK Key Country Dynamics
    • 5.6.2.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.2.3. Competitive Insights
    • 5.6.2.4. U.K. Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.3. Germany
    • 5.6.3.1. Germany Key Country Dynamics
    • 5.6.3.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.3.3. Competitive Insights
    • 5.6.3.4. Germany Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.4. France
    • 5.6.4.1. France Key Country Dynamics
    • 5.6.4.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.4.3. Competitive Insights
    • 5.6.4.4. France Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.5. Italy
    • 5.6.5.1. Italy Key Country Dynamics
    • 5.6.5.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.5.3. Competitive Insights
    • 5.6.5.4. Italy Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.6. Spain
    • 5.6.6.1. Spain Key Country Dynamics
    • 5.6.6.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.6.3. Competitive Insights
    • 5.6.6.4. Spain Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.7. Denmark
    • 5.6.7.1. Denmark Spain Key Country Dynamics
    • 5.6.7.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.7.3. Competitive Insights
    • 5.6.7.4. Denmark Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.8. Sweden
    • 5.6.8.1. Sweden Key Country Dynamics
    • 5.6.8.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.8.3. Competitive Insights
    • 5.6.8.4. Sweden Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.9. Norway
    • 5.6.9.1. Norway Key Country Dynamics
    • 5.6.9.2. Regulatory Landscape and Reimbursement Scenario
    • 5.6.9.3. Competitive Insights
    • 5.6.9.4. Norway Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Asia Pacific
  • 5.7.1. Asia Pacific Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.2. China
    • 5.7.2.1. China Key Country Dynamics
    • 5.7.2.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.2.3. Competitive Insights
    • 5.7.2.4. China Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.3. Japan
    • 5.7.3.1. Japan Key Country Dynamics
    • 5.7.3.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.3.3. Competitive Insights
    • 5.7.3.4. Japan Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.4. India
    • 5.7.4.1. India Key Country Dynamics
    • 5.7.4.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.4.3. Competitive Insights
    • 5.7.4.4. India Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.5. South Korea
    • 5.7.5.1. South Korea Key Country Dynamics
    • 5.7.5.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.5.3. Competitive Insights
    • 5.7.5.4. South Korea Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.6. Australia
    • 5.7.6.1. Australia Key Country Dynamics
    • 5.7.6.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.6.3. Competitive Insights
    • 5.7.6.4. Australia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.7. Thailand
    • 5.7.7.1. Thailand Key Country Dynamics
    • 5.7.7.2. Regulatory Landscape and Reimbursement Scenario
    • 5.7.7.3. Competitive Insights
    • 5.7.7.4. Thailand Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Latin America
  • 5.8.1. Latin America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.2. Brazil
    • 5.8.2.1. Brazil Key Country Dynamics
    • 5.8.2.2. Regulatory Landscape and Reimbursement Scenario
    • 5.8.2.3. Competitive Insights
    • 5.8.2.4. Brazil Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.3. Argentina
    • 5.8.3.1. Argentina Key Country Dynamics
    • 5.8.3.2. Regulatory Landscape and Reimbursement Scenario
    • 5.8.3.3. Competitive Insights
    • 5.8.3.4. Argentina Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Middle East and Africa (MEA)
  • 5.9.1. Middle East and Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9.2. South Africa
    • 5.9.2.1. South Africa Key Country Dynamics
    • 5.9.2.2. Regulatory Landscape and Reimbursement Scenario
    • 5.9.2.3. Competitive Insights
    • 5.9.2.4. South Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9.3. Saudi Arabia
    • 5.9.3.1. Saudi Arabia Key Country Dynamics
    • 5.9.3.2. Regulatory Landscape and Reimbursement Scenario
    • 5.9.3.3. Competitive Insights
    • 5.9.3.4. Saudi Arabia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9.4. UAE
    • 5.9.4.1. UAE Key Country Dynamics
    • 5.9.4.2. Regulatory Landscape and Reimbursement Scenario
    • 5.9.4.3. Competitive Insights
    • 5.9.4.4. UAE Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9.5. Kuwait
    • 5.9.5.1. Kuwait Key Country Dynamics
    • 5.9.5.2. Regulatory Landscape and Reimbursement Scenario
    • 5.9.5.3. Competitive Insights
    • 5.9.5.4. Kuwait Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments/ Strategic Initiatives & Impact Analysis by Key Market Participants
• 6.2. Company Categorization
• 6.3. Company Market Position Analysis
• 6.4. Strategy Mapping
• 6.5. Company Profiles
  • 6.5.1. AbbVie Inc.
    • 6.5.1.1. Participant's Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Recent Developments/ Strategic Initiatives
  • 6.5.2. Afaxys, Inc.
    • 6.5.2.1. Participant's Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Recent Developments/ Strategic Initiatives
  • 6.5.3. Agile Therapeutics
    • 6.5.3.1. Participant's Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Recent Developments/ Strategic Initiatives
  • 6.5.4. Bayer AG
    • 6.5.4.1. Participant's Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Recent Developments/ Strategic Initiatives
  • 6.5.5. China Resources (Holdings) Co., Ltd.
    • 6.5.5.1. Participant's Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Recent Developments/ Strategic Initiatives
  • 6.5.6. Church & Dwight Co., Inc.
    • 6.5.6.1. Participant's Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Recent Developments/ Strategic Initiatives
  • 6.5.7. Cupid Limited
    • 6.5.7.1. Participant's Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Recent Developments/ Strategic Initiatives
  • 6.5.8. Helm AG
    • 6.5.8.1. Participant's Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Recent Developments/ Strategic Initiatives
  • 6.5.9. Johnson & Johnson Services, Inc.
    • 6.5.9.1. Participant's Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Recent Developments/ Strategic Initiatives
  • 6.5.10. Organon Group
    • 6.5.10.1. Participant's Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Recent Developments/ Strategic Initiatives
  • 6.5.11. Pfizer Inc.
    • 6.5.11.1. Participant's Overview
    • 6.5.11.2. Financial Performance
    • 6.5.11.3. Product Benchmarking
    • 6.5.11.4. Recent Developments/ Strategic Initiatives
  • 6.5.12. Veru, Inc.
    • 6.5.12.1. Participant's Overview
    • 6.5.12.2. Financial Performance
    • 6.5.12.3. Product Benchmarking
    • 6.5.12.4. Recent Developments/ Strategic Initiatives
  • 6.5.13. Viatris Inc.
    • 6.5.13.1. Participant's Overview
    • 6.5.13.2. Financial Performance
    • 6.5.13.3. Product Benchmarking
    • 6.5.13.4. Recent Developments/ Strategic Initiatives

관련자료